Hematologic Malignancies Program The goal of the Program in Hematologic Malignancies is to develop a better understanding and improved treatments for this group of diseases. Four areas of focus predominate: (1) Developing a deeper understanding of the biologic basis of hematologic malignancies; (2) Using this understanding to develop better non- transplant therapies; (3) Discovering novel methods to overcome the current limitations of hematopoietic cell transplantation; and (4) Using these discoveries to improve the actual practice of hematopoietic cell transplantation. The Hematologic Malignancies program currently has 75 members from 11 departments and 3 institutions. Seventy-three Members (97%) have peer-reviewed funding or are the Principal Investigator on a clinical trial. The Hematologic Malignancies program currently has $24.3M in grant funding (direct dollars) of which $16.9M is peer-reviewed and $6.9M (40%) is from NCI. The Program published a total of 1218 papers in the previous grant period. 27% were intra-programmatic, 35% were inter-programmatic and 19% were inter- institutional. In 2012, 148,040 Americans were diagnosed with a hematologic malignancy, resulting in 54,380 deaths, making these malignancies collectively the second leading cause of cancer death after lung cancer (160,340), and exceeding in aggregate the deaths from colon (51,690), breast (39,920) pancreas (37,390), and prostate cancer (28,170). Previous work from our program has improved our understanding of this group of diseases, particularly the myeloid malignancies, leading to new approaches to screening for genetic abnormalities, improved monitoring of disease progression and novel therapeutics. Results from our studies have also led to a better understanding of the science behind problems of hematopoietic cell transplantation and provided methods to overcome some of these problems leading to improved cure rates. Members of this program also oversee a very busy clinical service, caring for 802 new patients in 2013 alone, of which 466 (58%) were treated on clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015704-44S2
Application #
9842503
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
He, Min
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Barault, Ludovic; Amatu, Alessio; Siravegna, Giulia et al. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67:1995-2005
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Molina, Yamile; Briant, Katherine J; Sanchez, Janeth I et al. (2018) Knowledge and social engagement change in intention to be screened for colorectal cancer. Ethn Health 23:461-479
Winters, Brian R; Vakar-Lopez, Funda; Brown, Lisha et al. (2018) Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol Oncol 36:342.e7-342.e14
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Baker, K Scott; Syrjala, Karen L (2018) Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program 2018:146-153
Miller, Chris P; Tsuchida, Connor; Zheng, Ying et al. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:610-620
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655

Showing the most recent 10 out of 1267 publications